Instruction 1(b).

FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Check this box if no longer subject to	STATEMENT OF CHANGES IN BENEFICIAL	<b>OWNERSHIP</b>
Section 16. Form 4 or Form 5		
obligations may continue. See		

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Doberstein Stephen K  (Last) (First) (Middle)  C/O NEKTAR THERAPEUTICS  455 MISSION BAY BOULEVARD SOUTH  (Street)					3. 10	NEKTAR THERAPEUTICS [ NKTR ]  3. Date of Earliest Transaction (Month/Day/Year)  10/05/2017  4. If Amendment, Date of Original Filed (Month/Day/Year)								Check all applicable)  Director  X Officer (give title other (specify below)  SVP & Chief Scientific Officer  6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person				ner pecify r
SAN FRANCE	ISCO		94158 (Zip)		-									Form filed by One Reporting Person Form filed by More than One Reporting Person				
(0.1.)		,		n-Deri	vativ	e Se	curit	ties Ar	nuired	Dis	ennsed o	of or Re	neficial	ly Owner				
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day			action	tion 2A. Deemed Execution Date,					es Acquired (A) or Of (D) (Instr. 3, 4 and 5		5. Amount of		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	v	Amount	(A) or (D)	Price	Transac (Instr. 3	tion(s)			iiisu. 4)
Common Stock <sup>(1)</sup> 10/05/2					5/2017	:017		М		43,677	A	\$9.53	3 74	74,779		D		
Common Stock <sup>(1)</sup> 10/05/2			5/2017	2017		S		43,677	D	\$24.97	31,102			D				
			Table II -								osed of, converti			Owned				
1. Title of Derivative Security (Instr. 3)  Conversion or Exercise Price of Derivative Security		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)				6. Date Exercisa Expiration Date (Month/Day/Yea		te	7. Title an of Securit Underlyin Derivative (Instr. 3 ar	ies g Security	8. Price of Derivative Security (Instr. 5)	ve derivativ Securitie	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Number of Shares					
Stock	\$9.53	10/05/2017			M			43,677	01/06/20:	14	01/05/2018	Common	43,677	\$0.00	396,32	23	D	

## **Explanation of Responses:**

- 1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for options expiring January 5, 2018.
- 2. This transaction was executed in multiple trades at prices ranging from \$24.96 to \$25.02. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

## Remarks:

Mark A. Wilson, Attorney-in-

**Fact** 

\*\* Signature of Reporting Person

10/10/2017 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.